Lipitor: 1113 Clinical Trials, Page 1 of 112

1 2 3 4 5 10 15 20  Last Page »

Hide Studies Not Open or Pending

3

Effectiveness of Atorvastatin in Preventing Cerebrovascular Events After Flow Diverter Implantation

Condition(s):Efficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year; Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year; All-cause Mortality Events (Within 1 Year); Incident Ischemic Stroke Events (Within 1 Year); New Hemorrhagic Stroke Events (Within 1 Year); New Stent Thrombosis Events (Within 1 Year); New Symptomatic Stenosis Events (Within 1 Year); Occurrence of In-stent Stenosis 12th ±1 Month Annual Angiographic Follow-up; Degree of In-stent Stenosis (as Measured by WASID Method) at the 12th ±1 Month Annual Angiographic Follow-up; Target Aneurysm Embolization Rate at 12±1 Month Annual Angiographic Follow-up (Raymond and OKM Classification)Last Updated:March 13, 2024Not yet recruiting

1 2 3 4 5 10 15 20  Last Page »

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.